Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Capricor Therap (CAPR)

Capricor Therap (CAPR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 102,035
  • Shares Outstanding, K 20,448
  • Annual Sales, $ 1,010 K
  • Annual Income, $ -7,640 K
  • 60-Month Beta 6.55
  • Price/Sales 121.51
  • Price/Cash Flow N/A
  • Price/Book 3.14
Trade CAPR with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +232,425.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.32 +50.30%
on 01/04/21
5.96 -16.28%
on 01/12/21
+0.77 (+18.25%)
since 12/15/20
3-Month
3.32 +50.30%
on 01/04/21
5.96 -16.28%
on 01/12/21
+0.12 (+2.46%)
since 10/15/20
52-Week
0.88 +467.05%
on 03/12/20
12.32 -59.50%
on 07/28/20
+3.20 (+178.77%)
since 01/15/20

Most Recent Stories

More News
Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications

--Capricor to leverage Lonza's expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply--

CAPR : 4.99 (+3.10%)
Thinking about buying stock in Capricor Therapeutics, Cardtronics, Clearside Biomedical, Ardelyx, or FuelCell Energy?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, CATM, CLSD, ARDX, and FCEL.

ARDX : 6.82 (-1.59%)
CATM : 40.71 (+0.20%)
CLSD : 4.01 (-4.52%)
FCEL : 15.84 (-10.00%)
CAPR : 4.99 (+3.10%)
Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for...

CAPR : 4.99 (+3.10%)
Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19

- Data Expected Second Quarter 2021 -

CAPR : 4.99 (+3.10%)
Capricor: 3Q Earnings Snapshot

BEVERLY HILLS, Calif. (AP) _ Capricor Therapeutics Inc. (CAPR) on Thursday reported a loss of $3.9 million in its third quarter.

CAPR : 4.99 (+3.10%)
Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Exosome Platform Technology

CAPR : 4.99 (+3.10%)
Capricor Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Capricor Therapeutics, Inc. (CAPR) (NASDAQ:CAPR) will be discussing their earnings results in their call to be held on November 12, 2020 at 4:30 PM Eastern...

CAPR : 4.99 (+3.10%)
Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19

Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins

CAPR : 4.99 (+3.10%)
Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12

Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases,...

CAPR : 4.99 (+3.10%)
Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020

--Final 12-Month Results from Phase II Trial to be Presented on October 1--

CAPR : 4.99 (+3.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

3rd Resistance Point 5.75
2nd Resistance Point 5.45
1st Resistance Point 5.22
Last Price 4.99
1st Support Level 4.69
2nd Support Level 4.39
3rd Support Level 4.16

See More

52-Week High 12.32
Fibonacci 61.8% 7.95
Fibonacci 50% 6.60
Fibonacci 38.2% 5.25
Last Price 4.99
52-Week Low 0.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar